


Participant flow



Baseline characteristics

		Perindopril (N= 86)	Placebo (N= 84)
Mean age (SD) (years)		76.3 (7.26)	75.1 (6.19)
Male sex (%)		32 (37)	39 (46)
Deprivation (SIMD quintile) (%)	Quintile 1 (Most deprived)	25 (29.1)	22 (26.2)
	Quintile 2	18 (20.9)	12 (14.3)
	Quintile 3	9 (10.5)	15 (17.9)
	Quintile 4	22 (25.6)	20 (23.8)
	Quintile 5 (Least deprived)	12 (14.0)	15 (17.9)
Living circumstances (%)	Home alone	40 (46.5)	36 (42.9)
	Home with family/friends	37 (43.0)	43 (51.2)
	Sheltered Housing	9 (10.4)	5 (6.0)
Walking aids (%)	None	51 (59.3)	49 (58.3)
	1 -2 stick	34 (39.7)	28 (33.3)
	Zimmer/tri wheeler	0 (0)	3 (3.6)
	Other	1 (1.2)	5 (6.0)
Median MMSE (IQR)		28 (27 – 29)	28 (27 – 29)
Number of medications (range)		5 (0-15)	5 (0-15)
BMI (kg/m ²) (SD)		28.0 (5.3)	29.2 (5.5)
Systolic BP (mmHg) (SD)		147 (19)	149 (20)
Diastolic BP (mmHg) (SD)		80 (14)	80 (11)
Creatinine (umol/L) (SD)		75 (15)	79 (19)
6 min walk distance (m) (SD)		300 (101)	312 (98)
Quadriceps strength (kg) (SD)		17.3 (10.7)	19.5 (11.6)
Handgrip strength (kg) (SD)		19.5 (7.5)	20.6 (8.8)
EQ5D		0.68 (0.23)	0.68 (0.23)
EQ-VAS		71 (16)	72 (16)
Short physical performance battery score (SD)		7.5 (1.7)	7.7 (2.0)
Functional limitations profile (SD)		852 (206)	868 (207)

Outcome measures

		Mean change from baseline (SD)			
		Perindopril	Placebo	Adjusted Treatment effect (95% CI)	p
<i>Primary outcome</i>					
6WD (m)	10 weeks	37 (63)	24 (55)	11 (-8 to 30)	0.27
	20 weeks	30 (75)	36 (59)	-9 (-30 to 13)	0.43
<i>Secondary outcomes</i>					
SPPB	10 weeks	1.4 (1.6)	1.2 (1.7)	0.1 (-0.4 to 0.7)	0.58
	20 weeks	1.0 (2.2)	1.1 (2.0)	-0.1 (-0.7 to 0.6)	0.79
Handgrip strength (kg)	10 weeks	0.6 (3.3)	1.1 (4.6)	-0.5 (-1.7 to 0.6)	0.34
	20 weeks	1.0 (3.5)	1.0 (5.2)	0.1 (-1.3 to 1.4)	0.94
Quadriceps strength (kg)	10 weeks	2.7 (12.5)	3.9 (14.0)	-1.7 (-5.2 to 1.9)	0.35
	20 weeks	0.1 (12.5)	2.0 (14.8)	-2.1 (-5.5 to 1.2)	0.21
FLP*	10 weeks	-80 (130)	-85 (144)	2 (-41 to 45)	0.93
	20 weeks	-66 (149)	-68 (149)	3 (-45 to 52)	0.90
EQ5D	10 weeks	0.07 (0.23)	0.06 (0.20)	0.01 (-0.05 to 0.07)	0.69
	20 weeks	0.05 (0.25)	0.05 (0.22)	0.00 (-0.06 to 0.06)	0.96
EQ5D VAS	10 weeks	5.5 (13.5)	1.9 (14.4)	3.1 (-0.8 to 7.1)	0.12
	20 weeks	1.2 (14.7)	1.9 (14.8)	-1.3 (-5.7 to 3.1)	0.56

*lower values indicate improvement

6WD: six-minute walk distance; SPPB: Short Physical Performance Battery; FLP: Functional Limitations Profile; EQ5D: Euroqol 5D; EQ-VAS: Euroqol visual analogue scale

Adverse events

Analysis confined to participants taking at least one dose of study medication

	Perindopril (n=85)	Placebo (n=79)
Cardiovascular	3	1
Cough	8	1
Dizziness	10	9
Falls	22	17
Fractures	3	1
Gastrointestinal	23	21
Infections	33	26
Musculoskeletal	33	31
Syncope	2	0
Total events	239	184
Number with at least one event	77	68